Clinical Trial Update: A Research Study to Evaluate Safety and Efficacy of DUR-928 in Subjects With Primary Sclerosing Cholangitis (PSC) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating safety and efficacy of DUR-928 in subjects with primary sclerosing cholangitis was terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sclerosing Cholangitis

Drugs mentioned

• DUR-928

Snippet

Sponsor: Durect | Conditions: Primary Sclerosing Cholangitis | Phase 2 | Status: TERMINATED | Results posted: 2022-10-17